AI Article Synopsis
- The global rise of cancer makes it the second leading cause of death, with nutrition playing a significant role in risk reduction.
- Changes in gut microbiota are linked to cancer risks and overall immunity, and certain diets like intermittent fasting, ketogenic, and Mediterranean are shown to positively impact microbiota and potential cancer prevention.
- While evidence is limited for the ketogenic diet's effect on microbiota, intermittent fasting and the Mediterranean diet may enhance gut health and improve the quality of life for cancer patients by activating cancer-fighting pathways.
Article Abstract
The prevalence of cancer is rising globally, and it is the second leading cause of death. Nutrition has an important influence on the risk of developing cancer. Moreover, changes in the gut microbiota are connected to the risk of developing cancer and are critical for sustaining immunity. Various studies have shown that intermittent fasting, ketogenic diet, and the Mediterranean diet are effective therapies in changing the intestinal microbiota, the prevention of cancer, and the improvement of tolerance to treatment in cancer patients. Although there is not enough evidence to show that the ketogenic diet is effective in changing the intestinal microbiota in a manner that could prevent cancer, intermittent fasting and the Mediterranean diet could positively affect composition of intestinal microbiota against cancer. In addition, the ketogenic diet, intermittent fasting, and the Mediterranean diet have the potential to stimulate anticarcinogenic pathways, and they might increase cancer patients' quality of life according to scientific evidence. In this review, we represent and argue recent scientific data on relationship between intermittent fasting, the ketogenic diet, and the Mediterranean diet, intestinal microbiota, cancer prevention and cancer treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CEJ.0000000000000820 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sustained weight reduction following 12 weeks of intermittent fasting intervention in people with insulin-treated type 2 diabetes-Two-year follow-up of the randomised controlled InterFast-2 trial.
Diabetes Obes Metab
January 2025
Interdisciplinary Metabolic Medicine Trials Unit, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
Intermittent fasting as a treatment for obesity in young people: a scoping review.
NPJ Metab Health Dis
December 2024
Children's Hospital Los Angeles and Keck School of Medicine of USC, Department of Pediatrics, Center for Endocrinology, Diabetes and Metabolism, Los Angeles, CA USA.
Intermittent fasting focuses on the timing of eating rather than diet quality or energy intake, with evidence supporting its effects on weight loss and improvements in cardiometabolic outcomes in adults with obesity. However, there is limited evidence for its feasibility and efficacy in young people. To address this, a scoping review was conducted to examine intermittent fasting regimens in individuals aged 10 to 25 for the treatment of obesity focusing on methodology, intervention parameters, outcomes, adherence, feasibility, and efficacy.
View Article and Find Full Text PDFAcute Intermittent Porphyria in an Adolescent Patient: Diagnostic and Treatment Challenges.
Cureus
November 2024
Internal Medicine-Pediatrics, University of California Los Angeles, Los Angeles, USA.
Acute intermittent porphyria (AIP) is a rare inherited metabolic disorder caused by decreased activity of the enzyme porphobilinogen deaminase in the heme synthesis pathway. This leads to the accumulation of toxic porphyrin precursors, such as porphobilinogen and δ-aminolevulinic acid. Clinical manifestations typically include episodic bouts of severe neurovisceral pain and autonomic dysfunction.
View Article and Find Full Text PDFGut-brain axis and brain health: modulating neuroinflammation, cognitive decline, and neurodegeneration.
3 Biotech
January 2025
Manipal Centre for Biotherapeutics Research, Manipal Academy of Higher Education, Karnataka Manipal, 576 104 India.
The microbiota-gut-brain axis is a pivotal medium of crosstalk between the central nervous system (CNS) and the gastrointestinal tract. It is an intricate network of synergistic molecular pathways that exert their effects far beyond their local vicinity and even affect the systemic functioning of the body. The current review explores the involvement of the gut-brain axis (GBA) in the functioning of the nervous system, with a special emphasis on the neurodegeneration, cognitive decline, and neuroinflammation that occur in Alzheimer's disease (AD) and Parkinson's disease (PD).
View Article and Find Full Text PDFObesity and Weight Loss Diets in Inflammatory Bowel Disease Patients: What Physicians Should Know.
J Gastrointestin Liver Dis
December 2024
Gastroenterology and Digestive Endoscopy Unit, S. Giovanni Addolorata Hospital, Via dell'Amba Aradam 8, Rome, Italy.
Nutritional approach has been intensely investigated in inflammatory bowel disease (IBD) patients, but, despite many sparse reports, at present, there is not a universally accepted specific diet. In fact, nutritional requirements and, therefore, the ideal diet, may vary according to disease type, extension and activity. Among nutritional related issue in IBD, obesity has become a relevant one.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!